137 related articles for article (PubMed ID: 35814857)
21. Value of surveillance studies for patients with stage I to II diffuse large B-cell lymphoma in the rituximab era.
Hiniker SM; Pollom EL; Khodadoust MS; Kozak MM; Xu G; Quon A; Advani RH; Hoppe RT
Int J Radiat Oncol Biol Phys; 2015 May; 92(1):99-106. PubMed ID: 25863757
[TBL] [Abstract][Full Text] [Related]
22. A multi-institutional and case-matched control study on treatment outcomes of consolidative radiotherapy after a full course of R-CHOP compared with R-CHOP alone in Stage I-II diffuse large B-cell lymphoma (KROG 17-02).
Chung MJ; Cho WK; Oh D; Eom KY; Kim JH; Kim WC; Lee JH
J Radiat Res; 2019 Oct; 60(5):677-684. PubMed ID: 31251343
[TBL] [Abstract][Full Text] [Related]
23. Hepatitis B Surface Antigen Positivity Is an Independent Unfavorable Prognostic Factor in Diffuse Large B-Cell Lymphoma in the Rituximab Era.
Cheng CL; Huang SC; Chen JH; Wei CH; Fang WQ; Su TH; Yuan CT; Liu JH; Chuang MK; Tien HF
Oncologist; 2020 Sep; 25(9):793-802. PubMed ID: 32275807
[TBL] [Abstract][Full Text] [Related]
24. Four cycles of R-CHOP followed by two applications of rituximab based on negative interim PET/CT: an analysis of a prospective trial.
Jin J; Ji D; Xia Z; Xue K; Zhang Q; Liu Y; Cao J; Hong X; Gu JJ; Guo Y; Lv F
BMC Cancer; 2022 Apr; 22(1):403. PubMed ID: 35418080
[TBL] [Abstract][Full Text] [Related]
25. Comparison of prognostic models for patients with diffuse large B-cell lymphoma in the rituximab era.
Huang YC; Liu CY; Lu HJ; Liu HT; Hung MH; Hong YC; Hsiao LT; Gau JP; Liu JH; Hsu HC; Chiou TJ; Chen PM; Tzeng CH; Yu YB
Ann Hematol; 2013 Nov; 92(11):1513-20. PubMed ID: 23775580
[TBL] [Abstract][Full Text] [Related]
26. Prognostic significance of interim ¹⁸F-FDG PET/CT after three or four cycles of R-CHOP chemotherapy in the treatment of diffuse large B-cell lymphoma.
Yang DH; Min JJ; Song HC; Jeong YY; Chung WK; Bae SY; Ahn JS; Kim YK; Bom HS; Chung IJ; Kim HJ; Lee JJ
Eur J Cancer; 2011 Jun; 47(9):1312-8. PubMed ID: 21334197
[TBL] [Abstract][Full Text] [Related]
27. Prognostic significance of bone marrow 2-[
Lim CH; Hyun SH; Cho YS; Choi JY; Lee KH
Clin Radiol; 2021 Jul; 76(7):550.e19-550.e28. PubMed ID: 33762136
[TBL] [Abstract][Full Text] [Related]
28. A new extranodal scoring system based on the prognostically relevant extranodal sites in diffuse large B-cell lymphoma, not otherwise specified treated with chemoimmunotherapy.
Hwang HS; Yoon DH; Suh C; Huh J
Ann Hematol; 2016 Aug; 95(8):1249-58. PubMed ID: 27167532
[TBL] [Abstract][Full Text] [Related]
29. Analysis of prognostic value of complete response by PET-CT and further stratification by clinical and biological markers in DLBCL patients.
Kanemasa Y; Shimoyama T; Sasaki Y; Tamura M; Sawada T; Omuro Y; Hishima T; Maeda Y
Med Oncol; 2017 Feb; 34(2):29. PubMed ID: 28083854
[TBL] [Abstract][Full Text] [Related]
30. [Comparison of prognostic models for patients with early-stage diffuse large B-cell lymphoma].
Liu W; Wang X; Zhang C; Xie Y; Lin N; Tu M; Ping L; Ying Z; Deng L; Huang H; Wu M; Sun Y; Du T; Leng X; Ding N; Zheng W; Song Y; Zhu J
Zhonghua Xue Ye Xue Za Zhi; 2016 Apr; 37(4):269-72. PubMed ID: 27093984
[TBL] [Abstract][Full Text] [Related]
31. High total metabolic tumor volume in PET/CT predicts worse prognosis in diffuse large B cell lymphoma patients with bone marrow involvement in rituximab era.
Song MK; Yang DH; Lee GW; Lim SN; Shin S; Pak KJ; Kwon SY; Shim HK; Choi BH; Kim IS; Shin DH; Kim SG; Oh SY
Leuk Res; 2016 Mar; 42():1-6. PubMed ID: 26851438
[TBL] [Abstract][Full Text] [Related]
32. [Evaluation of different staging systems and prognostic analysis of 110 primary gastrointestinal diffuse large B cell lymphoma].
Mao L; Wang X; Wang CY; Xia B; Ning QY; Yang HL; Yu Y; Zhang YZ
Zhonghua Yi Xue Za Zhi; 2019 Jun; 99(24):1853-1858. PubMed ID: 31269579
[No Abstract] [Full Text] [Related]
33. International prognostic indices in diffuse large B-cell lymphoma: a comparison of IPI, R-IPI, and NCCN-IPI.
Ruppert AS; Dixon JG; Salles G; Wall A; Cunningham D; Poeschel V; Haioun C; Tilly H; Ghesquieres H; Ziepert M; Flament J; Flowers C; Shi Q; Schmitz N
Blood; 2020 Jun; 135(23):2041-2048. PubMed ID: 32232482
[TBL] [Abstract][Full Text] [Related]
34. [The prognostic value of the international prognostic index, the national comprehensive cancer network IPI and the age-adjusted IPI in diffuse large B cell lymphoma].
Song JL; Wei XL; Zhang YK; Hao XX; Huang WM; Wei Q; Wei YQ; Feng R
Zhonghua Xue Ye Xue Za Zhi; 2018 Sep; 39(9):739-744. PubMed ID: 30369184
[No Abstract] [Full Text] [Related]
35. Value of
Jiang C; Teng Y; Chen J; Wang Z; Zhou Z; Ding C; Xu J
Ann Nucl Med; 2020 Dec; 34(12):911-919. PubMed ID: 33057996
[TBL] [Abstract][Full Text] [Related]
36. Positron Emission Tomography-Directed Therapy for Patients With Limited-Stage Diffuse Large B-Cell Lymphoma: Results of Intergroup National Clinical Trials Network Study S1001.
Persky DO; Li H; Stephens DM; Park SI; Bartlett NL; Swinnen LJ; Barr PM; Winegarden JD; Constine LS; Fitzgerald TJ; Leonard JP; Kahl BS; LeBlanc ML; Song JY; Fisher RI; Rimsza LM; Smith SM; Miller TP; Friedberg JW
J Clin Oncol; 2020 Sep; 38(26):3003-3011. PubMed ID: 32658627
[TBL] [Abstract][Full Text] [Related]
37. Reduced radiotherapy clinical benefit for primary Waldeyer's ring diffuse large B-cell lymphoma in the rituximab era.
Guan Q; Hong Y; Hu G; Zhou Q; Li L; Qian Z; Zhou S; Ren X; Qiu L; Wang X; Zhang H
Hematol Oncol; 2021 Oct; 39(4):490-497. PubMed ID: 33908077
[TBL] [Abstract][Full Text] [Related]
38. Interim fluorine-18 fluorodeoxyglucose PET-computed tomography and cell of origin by immunohistochemistry predicts progression-free and overall survival in diffuse large B-cell lymphoma patients in the rituximab era.
de Oliveira Costa R; Hallack Neto A; Siqueira S; Lage LA; de Paula HM; Coutinho AM; Pereira J
Nucl Med Commun; 2016 Oct; 37(10):1095-101. PubMed ID: 27281359
[TBL] [Abstract][Full Text] [Related]
39. Prognostic models integrating quantitative parameters from baseline and interim positron emission computed tomography in patients with diffuse large B-cell lymphoma: post-hoc analysis from the SAKK38/07 clinical trial.
Zucca E; Cascione L; Ruberto T; Facchinelli D; Schär S; Hayoz S; Dirnhofer S; Giovanella L; Bargetzi M; Mamot C; Ceriani L
Hematol Oncol; 2020 Dec; 38(5):715-725. PubMed ID: 32947651
[TBL] [Abstract][Full Text] [Related]
40. Primary gastric diffuse large B-cell Lymphoma (DLBCL): analyses of prognostic factors and value of pretreatment FDG-PET scan.
Chihara D; Oki Y; Ine S; Kato H; Onoda H; Taji H; Kagami Y; Yamamoto K; Morishima Y
Eur J Haematol; 2010 Jun; 84(6):493-8. PubMed ID: 20148943
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]